ReviewAsian journal of andrology
Chemotherapy and its evolving role in the management of advanced prostate cancer.
Review in Asian journal of andrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Metabolic Modulation by Dimethyl Fumarate Alters Docetaxel Responses in Prostate Cancer Cells.International journal of molecular sciences · 2026Article
- Targeting Prostate Cancer Metabolism Through Transcriptional and Epigenetic Modulation: A Multi-Target Approach to Therapeutic Innovation.International journal of molecular sciences · 2025Review
- An Experimental Rat Model for Simultaneous Induction of Peripheral Neuropathy and Myelotoxicity by Docetaxel Administration: Evaluating the Protective Role of Dimethyl Fumarate.International journal of molecular sciences · 2025Article
- Prostate-Specific Antigen Screening According to Health Professional Counseling and Age in the United States.Prostate cancer · 2022Article
- Anticancer Activity and Mechanisms of Action of New Chimeric EGFR/HDAC-Inhibitors.International journal of molecular sciences · 2021Article
- Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.PloS one · 2020Article
- Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes.Oncotarget · 2017Article
- Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer.Frontiers in bioscience (Elite edition) · 2017Article
- Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.Medical oncology (Northwood, London, England) · 2016Review
- Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel.Contemporary oncology (Poznan, Poland) · 2015Review
- Platycodin D induces tumor growth arrest by activating FOXO3a expression in prostate cancer in vitro and in vivo.Current cancer drug targets · 2015Article
- The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions.Asian journal of andrologyArticle
- From bench to bedside: bipolar androgen therapy in a pilot clinical study.Asian journal of andrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Advanced prostate cancer has been recognized as being responsive to androgen deprivation since the 1940s when Charles Huggins first described the role of surgical castration in managing these patients. However, androgen deprivation only results in transient disease control for the vast majority of men, with those progressing in spite of castrate testosterone levels labeled as having castrate-resistant prostate cancer (CRPC). Until 2004, the therapeutic arena for these patients had remained stagnant, with no agent having shown a survival gain in the CRPC setting. Two landmark publications changed the prostate cancer treatment landscape by providing 'level-1 evidence' that docetaxel-based chemotherapy led to prolongation in overall survival (OS). This was followed by the approval of cabazitaxel in 2010 on the basis of Phase III data demonstrating its efficacy in patients pretreated with docetaxel. More recently, a number of next-generation androgen-directed agents (e.g. abiraterone and enzalutamide) have also been shown to lead to a survival benefit in men with CRPC. With so many new treatment options available, a number of questions remain. These include: how to best sequence chemotherapy with these newer hormonal agents, the clinical implication of cross-resistance between taxanes and androgen-directed agents and which subsets of patients may benefit most from early use of chemotherapy. This review will provide an overview of the evolving role of chemotherapy in the management of advanced prostate cancer in the current era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.